CTRI/2025/06/089716尚未招募2 期
Efficacy and Safety of Habbe Gule Aak versus Habbe Suranjan in Primary Gout A Comparative Clinical Study
Govt Tibbi College And Hospital1 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2025年7月15日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Reduction of serum uric acid
研究概览
简要总结
After thorough screening, diagnosed patients of primary gout who fulfil inclusion criteria will be included in study. Patients will be included for the study. The patients will be randomly allocated in two groups 30 in test group (Habbe Gule Aak) and 30 in control group (Habbe Suranjan). Treatment will be given for 30 days in both groups. Objective Parameters will be assessed before and after treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Coin toss, Lottery, toss of dice, shuffling cards etc
- 盲法
- None
入排标准
- 年龄范围
- 30.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •1.Diagnosed cases of primary gout 2.serum uric acid more than 7.2% 3.Patients of either gender 4.Patients between 30 to 65 years of age Patients who have agreed to participate and sign the consent form.
排除标准
- •1.Pregnancy and lactation 2.Complicated cases of Gout 3.Co-morbid conditions of participants like Diabetic Ketoacidosis, Nephropathy, Coronary artery disease, Peripheral vascular disease, cerebrovascular disease and liver disease.
- •4.Immuno-compromised states like Malignancies, AIDS and on Immuno-suppressive agents.
- •5.Participants fail to attend treatment schedule regularly.
结局指标
主要结局
Reduction of serum uric acid
时间窗: at baseline i.e. 00th day(visit 1 ,7th day(visit 2), 14th day ( visit 3) and 30th day ( visit 4)
次要结局
- Change in different clinical symptoms of primary gout(7th, 14th, 21st, and 30th days)
研究者
DR HELAL ANWER
GOVERNMENT TIBBI COLLEGE AND HOSPITAL
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
Clinical effect of Langladyam Loham and Kaishor Guggul in Vatarakta.CTRI/2025/12/098719Dr. Pritesh Jaiswal120
招募中
1 期
A study in subjects with gout flares that investigates the effect, safety, tolerability, and pharmacokinetics (absorption, distribution, metabolism, and elimination) of a single dose of LEO 158968, a new compound that may potentially be used in the treatment of several autoinflammatory diseases2023-508793-29-00Leo Pharma A/S13
尚未招募
不适用
Orlistat and Weight Management for Uric Acid Control in Obese Gout: A RCTObesityNCT07326839XueMei Guo120
尚未招募
2 期
Huaier Granule and ProteinuriaNCT07355361Fudan University120
尚未招募
2/3 期
EVALUATE THE ROLE OF HOMOEOPATHIC MEDICINE IN CASES OF GOUTCTRI/2025/10/096619Sri Ganganagar Homoeopathic medical college hospital and Research centre80